SCHEMBL14009158

SCHEMBL14009158

COC(=O)c1ccc(NC(=O)c2ccc(C(=O)Nc3ccc(OC)cc3C)s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ TP53 P04637 2/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ PKM P14618 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ KDM4E B2RXH2 3/20 0.51
▸ MAPT P10636 3/20 0.51
▸ LMNA P02545 3/20 0.51
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ F10 P00742 1/20 0.47
▸ IL2 P60568 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009284 0.90 CA1 (0.50) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009330 0.88 MEN1 (0.52) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009320 0.85 MEN1 (0.52) RAB9ASMN1; SMN2MEN1KMT2ATP53
SCHEMBL14009231 0.85 MAPT (0.52) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009222 0.84 RXFP1 (0.51) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009173 0.84 KLKB1 (0.57) NPC1SMN1; SMN2MEN1KMT2APKM
SCHEMBL14009166 0.81 HRH3 (0.49) NPC1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL14009168 0.81 MAPT (0.57) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009239 0.80 RAB9A (0.56) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14009227 0.80 NPC1 (0.60) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 NPC1 4547/4885RAB9A 3846/4885SMN1; SMN2 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback